XOMA
NASDAQ HealthcareXOMA Royalty Corporation - Common Stock
Biotechnology
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets and commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
๐ Market Data
| Price | $41.38 |
|---|---|
| Volume | 374,548 |
| Market Cap | 501.91M |
| Beta | 0.680 |
| RSI (14-Day) | 63.2 |
| 200-Day MA | $31.13 |
| 50-Day MA | $32.27 |
| 52-Week High | $42.81 |
| 52-Week Low | $22.29 |
| P/E Ratio | 28.34 |
| Forward P/E | 19.34 |
| Price / Book | 5.85 |
๐ฏ Investment Strategy Scores
XOMA scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (69/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ Institutional Whale (13/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find XOMA in your text
Paste any article, transcript, or post โ the tool will extract XOMA and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.